Table 2 Baseline characteristics of the patient populations
Author | Intervention(s) | Total UPDRS score | UPDRS Mental score | UPDRS ADL score | UPDRS Motor score | Hoehn & Yahr scale | Schwab & England scale | Follow-up Duration (months) | Disease Duration (years) |
|---|---|---|---|---|---|---|---|---|---|
NINDS 2006 [22] | Creatine 10 g/d | 23.9(9.07) | 1.13(1.29) | 6.33(3.07) | 16.4(6.77) | 1.43(0.5) | 92.7(5.25) | 12 | Within 5 yrs |
Placebo | 22.8(9.63) | 1.13(1.19) | 6.03(3.45) | 15.6(7.01) | 1.46(0.5) | 94.2(4.81) | |||
Bender 2006 [21] | Creatine 4 g/d | 27.4(11.7) | 2.2(1.9) | 8.1(4.6) | 16.3(7.0) | 24 | Above 2 yrs | ||
Placebo | 27.4(17) | 1.6(1.5) | 7.8(4.8) | 17.4(11) | |||||
NINDS 2008 [20] | Creatine 10 g/d | 23.9(9.07) | 1.13(1.29) | 6.33(3.07) | 16.4(6.77) | 1.43(0.5) | 92.7(5.25) | 18 | Within 5 yrs |
Placebo | 22.8(9.63) | 1.13(1.19) | 6.03(3.45) | 15.6(7.01) | 1.46(0.5) | 94.2(4.81) | |||
Kieburtz 2015 [19] | Creatine 10 g/d | 26.5(11.7) | 1.3(1.4) | 7.3(4.1) | 17.9(8.6) | 90.9(6.6) | 60 | Within 5 yrs | |
Placebo | 25.9(11) | 1.3(1.4) | 7.0(3.8) | 17.6(8.1) | 91.4(6.3) | ||||
Li 2015 [18] | Creatine 10 g/d | 17.5(7.8) | 18 | Approximately 7.7 yrs | |||||
Placebo | 18.8(7.4) |